A 6-Month Randomized Clinical Trial Comparing the Ocular Hypotensive Effect of Bimatoprost 0.03% (Lumigan) and Dorzolamide 2% (Trusopt) in Glaucoma

Purpose: To compare the intraocular pressure lowering effect and safety of topical bimatoprost (0.03%) with dorsolamide (2%).Design: Unicenter, randomized, investigator-masked clinical trial.Methods: After washout of glaucoma medications, primary open angle glaucoma (POAG) patients randomly received bimatoprost 0.03% once daily and dorsolamide 2% twice daily for 6 months. The primary measure was mean change from base-line intra-ocular pressure (IOP) (8-12mmHg). Secondary measures included mean IOP, complete ophthalmic examination, adverse side effects and the prevalence of patients reaching specific target IOP.Results: Mean change from base-line IOP was significantly greater for patients on bimatoprost 0.03% than for those on dorzolamide 2% on each study visit. At the end of the study,70% of patients on bimatoprost 0.03% achieved a 20% reduction of the base-line IOP while with those on dorzolamide 2% the percentage was only 60%.Conclusion: Bimatoprost 0.03% is more effective than dorzolamide 2% in lowering the IOP in cases of POAG, and both drugs have proved to be well tolerated.